Osteoporosis Study Guide Flashcards
Vitamin D supplement for renal insufficiency
Calcitriol (activated form)
Vitamin D Supplement Amounts when > 30 ng/mL
400-1000 units 1-2x daily
Vitamin D Supplement Amounts when < 30 ng/mL
50,000 units 1-2x weekly until improved, then 400-1000 QD
3 Vit. D forms
Ergocalciferol; Cholecalciferol; Calcitriol
Vitamin D2
Ergocalciferol; OTC & Rx formulations
Vitamin D3
Cholecalciferol; OTC only - best for raising levels
Activated 1,25 dihydroxy
Calcitriol; Rx; Use with ESRD pts
Preferred Calcium Supplement
Calcium citrate; slightly more expensive than carbonate
Calcium Drug Interactions
Calcium decreases effectiveness of the following: Iron; Tetracyclines; FQs; Levothyroxine; Bisphosphonates; Phenytoin
1st Line Tx for Osteoporosis
Bisphosphonates
2nd Line Tx for Osteoporosis
Raloxifene (Evista)
Bisphosphonates MoA
Bind to bone matrix and reduce osteoclas activity (decrease resorption)
Types of fractures reduced by Bisphosphonates
Hip & Vertebral
Oral Bisphosphonate Contraindications
Esophageal abnormalities; Inability to sit up for 30 min
Oral & IV Bisphos Contraindications
Renal impairment; Hypocalcemia
Long term safety concerns for Bisphos
Osteonecrosis of jaw; atypical femoral fx; Esophageal CA; Limit to 5 yrs
Side Effects of All Bisphos
Hypocalcemia; MS pain; Flu-like s/sx
4 Bisphosphonates
Alendronate (Fosamax/Binosto); Ibandronate (Boniva); Risedronate (Actonel); Zoledronic Acid (Reclast/Zometa)
Alendronate (Fosamax/Binosto) dosing
PO daily or weekly
Ibandronate (Boniva) dosing
PO monthly or IV q3months
Risedronate (Actonel) dosing
PO qd; q1week; or q1month
Zoledronic acid (Reclast)
IV q1yr
Raloxifen (Evista) MoA
SERM = Selective estrogen-receptor modulator
Drug to avoid with Evista
Tamoxifen - same MoA
Types of fractures reduced by Raloxifene (Evista)
Vertebral fx only
Raloxifen (Evista) Route
PO qd
3rd line Osteoporosis tx
Calcitonin
Calcitonin MoA
Inhibits osteoclasts
Calcitonin Route
Intranasal spray qd; SC & IM also available
Newer Osteoporosis Drugs
Teriparatide (Forteo); Denosumab (Prolia)
Teriparatide (Forteo) MoA
PTH analogue; Stimulates osteoblasts to form new bone
Teriparatide (Forteo) Drawbacks
Route (SC qd); Length of use (2 yrs); Contraindications (Cancer; kids; ^ Alk phos; prior skeletal radiation; hypercalciuria); AEs (Leg cramps)
Denosumab (Prolia) MoA
Prevents resorption - Monoclonal AB inhibiting RANKL protein
Denosumab (Prolia) Advantages
q6mo administration; Reversible
Denosumab (Prolia) Drawbacks
Associated with (atypical fx, osteonecrosis of jaw); Contraindications (Hypocalcemia, Pregnancy, CrCl <30 ml/min)